Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance.
about
Physiologically based pharmacokinetic modeling framework for quantitative prediction of an herb-drug interaction.Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifenMidazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans.Gender differences in drug effects: implications for anesthesiologists."Cocktail" approaches and strategies in drug development: valuable tool or flawed science?A retrospective review of the use of alfentanil in a hospital palliative care setting.Functional evolution of the pregnane X receptor.Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction.Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanilGender and interindividual variability in pharmacokinetics.Sedation for critically ill or injured adults in the intensive care unit: a shifting paradigm.CYP3A activity: towards dose adaptation to the individual.Simultaneous determination of alfentanil and midazolam in human plasma using liquid chromatography and tandem mass spectrometryInfluence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine.Interindividual and intraindividual variability of the urinary 6beta-Hydroxycortisol/Cortisol ratio in Chinese subjects: implications of its use for evaluating CYP3A activity.Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity.Reduced exposure variability of the CYP3A substrate simvastatin by dose individualization to CYP3A activity.A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.
P2860
Q33702513-E0798268-05BE-430D-9063-B20D323CBF4BQ34571065-62310F00-583D-483B-A2B6-2C374442DD06Q35023726-C0A98C33-A39F-44B7-89A0-F99FE186D18FQ35089206-B8FC4EEF-80B5-498B-AC44-92EECE905883Q35640730-B6431C7F-3828-4955-9218-863DF8FEF820Q35903982-C9E9BB9E-FE2E-4A04-87E5-82E094E9862AQ36440155-39F7E364-7D97-476B-8DD2-EEDC31E11DB0Q36578060-2BD349ED-C774-4629-8DF4-04945CA1FAA2Q36646017-A8D35BB5-0D03-4C3F-A6A3-E422B72A9483Q37550556-5A0B4EFA-6BA0-43C4-82B3-EDBED988B410Q38040844-2F678FD7-5C41-4AE7-A5C1-984486A064B0Q38763583-7F8D3730-1D90-4855-A14D-C205FBC081C4Q41985982-846A6DC0-F21F-4A8D-AB23-297A57CAA81AQ44200712-C8E1EA49-01E9-4742-A4A5-AE8E33EF8D5DQ45151697-8E43C5DF-EF14-4532-8D78-14FEAC7D2617Q46711328-CEF66D6A-73CD-4B37-A630-2ADDD170AEB8Q47793459-F244428E-E0A1-48D4-A77E-5E2E4D656CBCQ48025123-EE37E77B-BF7A-48BB-8FFD-9362E28037A4
P2860
Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Intraindividual variability in ...... tanil and midazolam clearance.
@en
Intraindividual variability in ...... tanil and midazolam clearance.
@nl
type
label
Intraindividual variability in ...... tanil and midazolam clearance.
@en
Intraindividual variability in ...... tanil and midazolam clearance.
@nl
prefLabel
Intraindividual variability in ...... tanil and midazolam clearance.
@en
Intraindividual variability in ...... tanil and midazolam clearance.
@nl
P2093
P2860
P1476
Intraindividual variability in ...... tanil and midazolam clearance.
@en
P2093
P2860
P304
P356
10.1177/00912709922008290
P577
1999-07-01T00:00:00Z